Abstract
Parkinson’s disease (PD) is associated with neurodegeneration of the nigrostriatal tract and is accompanied with loss of tyrosine hydroxylase (TH) and dopamine (DA). Development of neuroprotective strategies targeting PD is often undermined by lack of proper understanding of processes contributing to the pathology. In this mini review we have tried to briefly outline the involvement of TH and α-synuclein in PD. Aberrant expression of α-synuclein is toxic to dopaminergic neurons. It interacts with ubiquitin-proteasomal processing system, implicated in oxidative injury and mitochondrial dysfunction which ultimately induce neurodegenration and cell death. The contributions of DJ-1 in TH regulation have also been discussed. Brain specific TH expression with the combined use of the pegylated immunoliposome (PILs) gene transfer technology and brain specific promoters as a new approach to treat PD has also been included.
Keywords: Tyrosine hydroxylase, dopamine, nigrostriatal pathway, alpha-synuclein, neurodegeneration, Parkinson’s disease.
CNS & Neurological Disorders - Drug Targets
Title:A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
Volume: 11 Issue: 4
Author(s): Wajihullah Khan, Medha Priyadarshini, Haytham A. Zakai, Mohammad A. Kamal and Qamre Alam
Affiliation:
Keywords: Tyrosine hydroxylase, dopamine, nigrostriatal pathway, alpha-synuclein, neurodegeneration, Parkinson’s disease.
Abstract: Parkinson’s disease (PD) is associated with neurodegeneration of the nigrostriatal tract and is accompanied with loss of tyrosine hydroxylase (TH) and dopamine (DA). Development of neuroprotective strategies targeting PD is often undermined by lack of proper understanding of processes contributing to the pathology. In this mini review we have tried to briefly outline the involvement of TH and α-synuclein in PD. Aberrant expression of α-synuclein is toxic to dopaminergic neurons. It interacts with ubiquitin-proteasomal processing system, implicated in oxidative injury and mitochondrial dysfunction which ultimately induce neurodegenration and cell death. The contributions of DJ-1 in TH regulation have also been discussed. Brain specific TH expression with the combined use of the pegylated immunoliposome (PILs) gene transfer technology and brain specific promoters as a new approach to treat PD has also been included.
Export Options
About this article
Cite this article as:
Khan Wajihullah, Priyadarshini Medha, A. Zakai Haytham, A. Kamal Mohammad and Alam Qamre, A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain, CNS & Neurological Disorders - Drug Targets 2012; 11 (4) . https://dx.doi.org/10.2174/187152712800792929
DOI https://dx.doi.org/10.2174/187152712800792929 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Humanized Mouse Models of HIV-1 Latency
Current HIV Research Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models
Inflammation & Allergy - Drug Targets (Discontinued) Nucleic Acid-Based Therapeutics for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Antiviral Nucleoside and Nucleotide Therapeutics
Current Topics in Medicinal Chemistry Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial
CNS & Neurological Disorders - Drug Targets Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment
CNS & Neurological Disorders - Drug Targets CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Reporting Rates of Yellow Fever Vaccine 17D or 17DD-Associated Serious Adverse Events in Pharmacovigilance Data Bases: Systematic Review
Current Drug Safety Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia
Current Pharmaceutical Design First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects
Current Clinical Pharmacology Novel Antiviral Strategies to Combat Human Arenavirus Infections
Current Molecular Medicine Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research Chimeric T Helper-B Cell Peptides Induce Protective Response Against Japanese Encephalitis Virus in Mice
Protein & Peptide Letters Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science